Disclosures for "Benefit Continues to Accumulate When Treatment is Continued Beyond Plaque Clearance – Estimating Accumulating or Maintained Treatment Benefit in the CLARITY AD and TRAILBLAZER-ALZ2 Trials"
-
Dr. Hendrix has received personal compensation for serving as an employee of Pentara Corporation. Dr. Hendrix has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pentara Corporation. Dr. Hendrix has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Pentara Corporation. The institution of Dr. Hendrix has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Pentara Corporation. Dr. Hendrix has or had stock in Pentara.
-
The institution of Mr. Whetten has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eisai.
-
Kent Hendrix has received personal compensation for serving as an employee of Pentara Corporation. The institution of an immediate family member of Kent Hendrix has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai.
-
Mr. Dickson has nothing to disclose.